Osteoporosis Screening & Treatment: When To Test, What Works, And How To Protect Your Bones In 2026

If you’re wondering when to get checked for osteoporosis, which tests actually matter, and how to prevent fractures as you age, you’re in the right place. Osteoporosis screening & treatment have evolved, and 2026 brings clearer guidance on who should be tested, how to interpret results, and which therapies truly reduce fracture risk. This guide gives you practical steps to protect your bones, what to expect at screening, how to gauge your personal risk, and the lifestyle and medication options that work, so you can stay strong, steady, and independent.

What Osteoporosis Is And Who Is At Risk

Osteoporosis is a disease where bones lose density and quality, making them fragile and more likely to break from a minor fall, or sometimes a simple cough or bend. You can’t feel bone loss, so many people don’t know they have osteoporosis until the first fracture.

You’re more likely to develop osteoporosis if you’re a postmenopausal woman, an adult over 65, or you have risk factors such as a prior low‑trauma (fragility) fracture, long‑term steroid use, low body weight, smoking, excessive alcohol use, rheumatoid arthritis, hyperthyroidism, hyperparathyroidism, malabsorption (like celiac disease), or chronic kidney or liver disease. Family history matters, too, especially a parent with a hip fracture.

Men are under‑screened but not immune. Bone loss accelerates with age, certain medications (androgen deprivation therapy, proton pump inhibitors, some anticonvulsants), and chronic illnesses. The good news: you can measure risk, track bone density, and treat bone loss before a fracture happens.

When And How To Get Screened

Who Should Be Screened And When

• Women 65 and older: get a baseline bone mineral density (BMD) test.
• Postmenopausal women under 65: get screened if you have risk factors (low body weight, prior fracture, high FRAX score, steroid use, smoking, etc.).
• Men 70 and older: many specialty guidelines recommend screening: at 50–69, screen if you have risk factors (prior fracture, steroids, hypogonadism, smoking, heavy alcohol use).
• Anyone over 50 with a fragility fracture (e.g., wrist, vertebral, hip): evaluate for osteoporosis and start prevention/treatment.
• People starting or taking ≥3 months of glucocorticoids (e.g., prednisone ≥2.5–5 mg/day): screen early and consider preventive therapy.

Screening intervals vary. If your BMD is normal or shows mild osteopenia, you may recheck in 3–5 years: if you’re closer to osteoporosis or at higher risk, every 1–2 years is typical.

Tests That Detect Bone Loss (DEXA, VFA, FRAX)

• DEXA (DXA): the gold‑standard, low‑radiation scan that measures BMD at your hip and spine. It’s quick (about 10 minutes) and painless.
• VFA (Vertebral Fracture Assessment): a low‑dose spine image often added to DEXA to spot silent vertebral fractures that dramatically raise future fracture risk.
• FRAX: an online calculator that estimates your 10‑year fracture probability using your age, sex, BMD (if available), and risk factors. It helps guide treatment decisions, especially if you’re in the “osteopenia” range.

Tip: Bring your height history. Losing more than 1.5–2 inches could hint at vertebral fractures.

Interpreting Results: T‑Scores, Z‑Scores, And Fragility Fractures

• T‑score compares your BMD to a healthy young adult:
• Normal: ≥ −1.0
• Osteopenia (low bone mass): between −1.0 and −2.5
• Osteoporosis: ≤ −2.5
• Z‑score compares your BMD to people your age/sex. It’s most useful in premenopausal women and men under 50 to look for unexpected bone loss that warrants a search for secondary causes.
• Fragility fractures (hip, spine, humerus, wrist after a low‑energy fall) are diagnostic of osteoporosis regardless of T‑score.

In the U.S., treatment is generally recommended for anyone with a hip or vertebral fracture, a T‑score ≤ −2.5, or osteopenia plus a FRAX 10‑year risk ≥3% for hip fracture or ≥20% for major osteoporotic fracture.

Confirming The Diagnosis And Assessing Fracture Risk

Baseline Lab Work To Rule Out Secondary Causes

Before you and your clinician lock in a plan, basic labs help uncover treatable reasons for bone loss. Typical tests include: calcium, creatinine/eGFR, 25‑hydroxyvitamin D, alkaline phosphatase, thyroid‑stimulating hormone, complete blood count, liver enzymes, and in selected cases PTH, celiac serologies, SPEP/UPEP (myeloma screen), testosterone (men), and 24‑hour urine calcium. Correct low vitamin D and calcium imbalances first.

Risk Stratification: Low, Moderate, High, And Very High Risk

• Low risk: normal BMD or mild osteopenia with low FRAX risk. Focus on lifestyle and recheck later.
• Moderate risk: osteopenia with intermediate FRAX probability. Consider treatment if risk is near thresholds or additional risks exist (steroids, high fall risk).
• High risk: T‑score ≤ −2.5 or FRAX above treatment thresholds, or presence of a vertebral fracture.
• Very high risk: multiple fractures, a recent fracture (within 12 months), very low T‑scores (e.g., < −3.0), or fractures while on therapy. These patients often benefit from starting with anabolic or dual‑action therapy and then consolidating with antiresorptives.

Treatment Options: Lifestyle Foundations And Medications That Work

Lifestyle Pillars: Calcium, Vitamin D, Nutrition, Exercise, And Fall Prevention

• Calcium: aim for about 1,200 mg/day (diet first: supplement if your intake falls short). Split doses if supplementing.
• Vitamin D: many adults need 800–2,000 IU/day to maintain 25‑OH vitamin D ≥30 ng/mL, but personalize with your clinician.
• Nutrition: prioritize protein (muscle supports bone), produce, and sources of calcium (dairy, fortified alternatives, leafy greens). Limit excess sodium and soda.
• Exercise: combine progressive resistance training, weight‑bearing impact as tolerated, and balance work (tai chi, yoga, single‑leg stance). Avoid deep spinal flexion if you have vertebral fractures.
• Fall prevention: review medications, check vision, declutter floors, add grab bars and good lighting, consider physical therapy for gait/balance.

Lifestyle alone can’t fix established osteoporosis, but it’s the base that makes medications safer and more effective.

Antiresorptives: Bisphosphonates, Denosumab, And SERMs

• Bisphosphonates (alendronate, risedronate, zoledronic acid): first‑line for many. They slow bone breakdown and reduce spine and hip fractures. Oral options are weekly or monthly: IV is yearly. Not ideal with severe kidney disease (eGFR <30–35 mL/min) or significant esophageal disorders (for oral forms).
• Denosumab: a twice‑yearly injection that reduces spine and hip fractures and is safe in reduced kidney function, but it can cause hypocalcemia, especially in advanced CKD, so vitamin D/calcium repletion is essential. Don’t stop abruptly: transition to a bisphosphonate to prevent rapid bone loss and rebound vertebral fractures.
• SERMs (raloxifene): reduce vertebral fractures and may lower breast cancer risk in certain women but don’t prevent hip fractures and can raise the risk of blood clots.

Anabolic And Dual‑Action Therapies: Teriparatide, Abaloparatide, Romosozumab

• Teriparatide and Abaloparatide: daily injections that build new bone and reduce vertebral and non‑vertebral fractures. Used for up to 2 years, then followed by an antiresorptive to maintain gains.
• Romosozumab: monthly injections for up to 12 months: both builds bone and reduces resorption. It rapidly increases BMD and lowers vertebral and clinical fracture risk. Avoid if you’ve had a recent heart attack or stroke: ensure calcium/vitamin D are adequate.

Choosing And Sequencing Therapy Based On Risk And Patient Factors

• High risk without recent fracture: start with a bisphosphonate (oral or IV) or denosumab. Consider cost, adherence, kidney function, GI tolerance, and convenience.
• Very high risk or multiple fractures: consider starting with an anabolic (teriparatide/abaloparatide) or romosozumab for 12–24 months, then switch to a potent antiresorptive to lock in gains.
• Glucocorticoid users: begin therapy promptly, even with osteopenia, because fracture risk rises quickly.
• Men: similar approach: check testosterone and treat hypogonadism if present, but don’t delay bone‑directed therapy if fracture risk is high.

Your best plan balances fracture reduction, safety, convenience, cost, and your preferences. The right sequence matters as much as the drug you choose.

Monitoring Progress, Safety, And How Long To Treat

BMD Rechecks, Bone Turnover Markers, And Drug Holidays

• Recheck DEXA every 1–2 years to confirm you’re gaining or maintaining BMD and not fracturing.
• Bone turnover markers (e.g., P1NP, CTX) can show early response or adherence within 3–6 months.
• Drug holidays: after 3–5 years of oral or 3 years of IV bisphosphonate, lower‑risk patients may pause with close monitoring. Not for denosumab, if stopping, give a bisphosphonate to prevent rebound.

Safety Considerations: Atypical Femur Fracture, ONJ, Hypocalcemia, And Adherence

• Rare events: atypical femur fractures and osteonecrosis of the jaw (ONJ) occur infrequently, usually with long‑term antiresorptive use. Report new thigh/groin pain, and complete major dental work before starting high‑potency therapy if possible.
• Hypocalcemia risk rises with denosumab/romosozumab and in CKD, optimize vitamin D and calcium first.
• Adherence is everything. Missed doses or stopping abruptly erases benefits. Set reminders, simplify regimens, and schedule follow‑ups.

Special Situations And Practical Next Steps

Glucocorticoid‑Induced Osteoporosis, Men, Premenopausal Women, And CKD

• Glucocorticoids: even low doses for ≥3 months raise fracture risk. Ensure calcium/vitamin D and start pharmacologic therapy sooner, often with a bisphosphonate or, for very high risk, an anabolic first.
• Men: screen and treat based on risk. Evaluate for hypogonadism: do not rely on testosterone alone if fracture risk is high.
• Premenopausal women: use Z‑scores: search for secondary causes (thyroid, celiac, meds). Pharmacotherapy is individualized and often reserved for fractures or very low BMD after other causes are addressed.
• CKD: avoid bisphosphonates when eGFR is severely reduced: denosumab is effective but monitor calcium closely. Coordinate with nephrology in advanced CKD.

Post‑Fracture Care, Fall‑Proofing Your Home, And Working With Your Clinician

• After any fragility fracture, start secondary prevention: DEXA/VFA, labs, vitamin D/calcium, and timely medication.
• Fall‑proofing checklist: secure rugs, clear cords, install grab bars and railings, improve lighting, wear supportive shoes, and practice balance exercises.
• Team up with your clinician: agree on a target (prevent hip/spine fractures), pick a therapy you can stick with, schedule BMD checks, and know the plan if you need to pause or switch.

Conclusion

You can’t control everything that affects your bones, but you can control screening and treatment. In 2026, the most reliable path is simple: get the right test (DEXA ± VFA), know your risk (including FRAX), build strong foundations (nutrition, exercise, fall prevention), and use the right medicine at the right time, and in the right sequence. Start now, before the first fracture, and give your future self steadier steps and stronger bones.

Rikin Shah

Stay updated by joining our newsletter